On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Phase 1 Trial in Non-Muscle Invasive Bladder Cancer, and Submit IND for Choroidal Metastases CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 12, 2022-- Aura Biosciences Inc.

Preclinical studies support further development of AU-011 for choroidal metastasis CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive

On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022 Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) John Maraganore , Ph.D., Joins

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European Commission has granted Orphan

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced it will host a virtual Investor Day on Tuesday,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive

Company on Track to Initiate Phase 1 Clinical Trial in 2H 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive